MAP2K7 and acute myeloid leukemia: The MEK inhibitor binimetinib has been shown to be safe in RAS-mutated AML, with very limited activity as monotherapy and in combination with the ATP-competitive pan-AKT inhibitor GSK2141795 (targeting the PI3K/PTEN/AKT/mTOR pathway) [201,202].